Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study.

Aging and disease

Giulia P, Michele L, Andrea F, Grazia D, Filomena C, Francesco P, Leandro C, Maria U, Carolina G, Massimiliano C, Antonio G.
PMID: 27493830
Aging Dis. 2015 Nov 24;7(4):318-25. doi: 10.14336/AD.2015.1124. eCollection 2016 Aug.

Cortical atrophy, neuronal loss, beta-amyloid deposition, neuritic plaques, and neurofibrillary tangles are neuropathological key features in the Alzheimer's disease (AD). Antibodies against beta-amyloid, neurotransmitters, microvascular endothelium components and microglial cells have been detected in AD serum suggesting that AD...

Cite
Giulia P, Michele L, Andrea F, et al. Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study. Aging Dis. 2015;7(4):318-25doi: 10.14336/AD.2015.1124.
Giulia, P., Michele, L., Andrea, F., Grazia, D., Filomena, C., Francesco, P., Leandro, C., Maria, U., Carolina, G., Massimiliano, C., & Antonio, G. (2016). Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study. Aging and disease, 7(4), 318-25. https://doi.org/10.14336/AD.2015.1124
Giulia, Paroni, et al. "Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study." Aging and disease vol. 7,4 (2016): 318-25. doi: https://doi.org/10.14336/AD.2015.1124
Giulia P, Michele L, Andrea F, Grazia D, Filomena C, Francesco P, Leandro C, Maria U, Carolina G, Massimiliano C, Antonio G. Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study. Aging Dis. 2015 Nov 24;7(4):318-25. doi: 10.14336/AD.2015.1124. eCollection 2016 Aug. PMID: 27493830; PMCID: PMC4963186.
Copy Download .nbib Format: NLM
Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers.

Journal of clinical medicine

Tiscia G, Sartori MT, Giuffrida G, Ostuni A, Cascavilla N, Nicolosi D, Battista C, Santeramo TM, Melillo L, Giordano G, Cappucci F, Fischetti L, Chinni E, Tarantini G, Cerbo A, Bertomoro A, Fabris F, Grandone E.
PMID: 34884404
J Clin Med. 2021 Dec 04;10(23). doi: 10.3390/jcm10235702.

Immune-mediated thrombotic thrombocytopenic purpura is a rare and challenging hematological disease caused by the antibody anti-ADAMTS13. Though the mortality rate has decreased considerably in recent years, fatalities still remain unacceptable. This study aimed at further adding to the existing...

Cite
Tiscia G, Sartori MT, Giuffrida G, et al. Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers. J Clin Med. 2021;10(23)doi: 10.3390/jcm10235702.
Tiscia, G., Sartori, M. T., Giuffrida, G., Ostuni, A., Cascavilla, N., Nicolosi, D., Battista, C., Santeramo, T. M., Melillo, L., Giordano, G., Cappucci, F., Fischetti, L., Chinni, E., Tarantini, G., Cerbo, A., Bertomoro, A., Fabris, F., & Grandone, E. (2021). Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers. Journal of clinical medicine, 10(23), . https://doi.org/10.3390/jcm10235702
Tiscia, Giovanni, et al. "Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers." Journal of clinical medicine vol. 10,23 (2021). doi: https://doi.org/10.3390/jcm10235702
Tiscia G, Sartori MT, Giuffrida G, Ostuni A, Cascavilla N, Nicolosi D, Battista C, Santeramo TM, Melillo L, Giordano G, Cappucci F, Fischetti L, Chinni E, Tarantini G, Cerbo A, Bertomoro A, Fabris F, Grandone E. Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers. J Clin Med. 2021 Dec 04;10(23). doi: 10.3390/jcm10235702. PMID: 34884404.
Copy Download .nbib Format: NLM
Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease.

Cancers

Maurillo L, Bassan R, Cascavilla N, Ciceri F.
PMID: 31548502
Cancers (Basel). 2019 Sep 23;11(10). doi: 10.3390/cancers11101417.

No abstract available.

Cite
Maurillo L, Bassan R, Cascavilla N, et al. Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease. Cancers (Basel). 2019;11(10)doi: 10.3390/cancers11101417.
Maurillo, L., Bassan, R., Cascavilla, N., & Ciceri, F. (2019). Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease. Cancers, 11(10), . https://doi.org/10.3390/cancers11101417
Maurillo, Luca, et al. "Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease." Cancers vol. 11,10 (2019). doi: https://doi.org/10.3390/cancers11101417
Maurillo L, Bassan R, Cascavilla N, Ciceri F. Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease. Cancers (Basel). 2019 Sep 23;11(10). doi: 10.3390/cancers11101417. PMID: 31548502; PMCID: PMC6826465.
Copy Download .nbib Format: NLM
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.

Oncotarget

Broccoli A, Casadei B, Morigi A, Sottotetti F, Gotti M, Spina M, Volpetti S, Ferrero S, Spina F, Pisani F, Merli M, Visco C, Paolini R, Zilioli VR, Baldini L, Di Renzo N, Tosi P, Cascavilla N, Molica S, Ilariucci F, Rigolin GM, D'Alò F, Vanazzi A, Santambrogio E, Marasca R, Mastrullo L, Castellino C, Desabbata G, Scortechini I, Trentin L, Morello L, Argnani L, Zinzani PL.
PMID: 29805746
Oncotarget. 2018 May 04;9(34):23443-23450. doi: 10.18632/oncotarget.25215. eCollection 2018 May 04.

Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive disease, hardly curable with standard chemo-immunotherapy. Current approaches have greatly improved patients' outcomes, nevertheless the disease is still characterized by high relapse rates. Before approval...

Cite
Broccoli A, Casadei B, Morigi A, et al. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Oncotarget. 2018;9(34):23443-23450doi: 10.18632/oncotarget.25215.
Broccoli, A., Casadei, B., Morigi, A., Sottotetti, F., Gotti, M., Spina, M., Volpetti, S., Ferrero, S., Spina, F., Pisani, F., Merli, M., Visco, C., Paolini, R., Zilioli, V. R., Baldini, L., Di Renzo, N., Tosi, P., Cascavilla, N., Molica, S., Ilariucci, F., Rigolin, G. M., D'Alò, F., Vanazzi, A., Santambrogio, E., Marasca, R., Mastrullo, L., Castellino, C., Desabbata, G., Scortechini, I., Trentin, L., Morello, L., Argnani, L., & Zinzani, P. L. (2018). Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Oncotarget, 9(34), 23443-23450. https://doi.org/10.18632/oncotarget.25215
Broccoli, Alessandro, et al. "Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma." Oncotarget vol. 9,34 (2018): 23443-23450. doi: https://doi.org/10.18632/oncotarget.25215
Broccoli A, Casadei B, Morigi A, Sottotetti F, Gotti M, Spina M, Volpetti S, Ferrero S, Spina F, Pisani F, Merli M, Visco C, Paolini R, Zilioli VR, Baldini L, Di Renzo N, Tosi P, Cascavilla N, Molica S, Ilariucci F, Rigolin GM, D'Alò F, Vanazzi A, Santambrogio E, Marasca R, Mastrullo L, Castellino C, Desabbata G, Scortechini I, Trentin L, Morello L, Argnani L, Zinzani PL. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Oncotarget. 2018 May 04;9(34):23443-23450. doi: 10.18632/oncotarget.25215. eCollection 2018 May 04. PMID: 29805746; PMCID: PMC5955107.
Copy Download .nbib Format: NLM
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients.

Clinical cancer research : an official journal of the American Association for Cancer Research

Zaccaria GM, Bertamini L, Petrucci MT, Offidani M, Corradini P, Capra A, Romano A, Liberati AM, Mannina D, de Fabritiis P, Cascavilla N, Ruggeri M, Mina R, Patriarca F, Benevolo G, Belotti A, Gaidano G, Nagler A, Hájek R, Spencer A, Sonneveld P, Musto P, Boccadoro M, Gay F.
PMID: 33926915
Clin Cancer Res. 2021 Jul 01;27(13):3695-3703. doi: 10.1158/1078-0432.CCR-21-0134. Epub 2021 Apr 29.

PURPOSE: Despite the improvement of therapeutic regimens, several patients with multiple myeloma (MM) still experience early relapse (ER). This subset of patients currently represents an unmet medical need.EXPERIMENTAL DESIGN: We pooled data from seven European multicenter phase II/III clinical...

Cite
Zaccaria GM, Bertamini L, Petrucci MT, et al. Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. Clin Cancer Res. 2021;27(13):3695-3703doi: 10.1158/1078-0432.CCR-21-0134.
Zaccaria, G. M., Bertamini, L., Petrucci, M. T., Offidani, M., Corradini, P., Capra, A., Romano, A., Liberati, A. M., Mannina, D., de Fabritiis, P., Cascavilla, N., Ruggeri, M., Mina, R., Patriarca, F., Benevolo, G., Belotti, A., Gaidano, G., Nagler, A., Hájek, R., Spencer, A., Sonneveld, P., Musto, P., Boccadoro, M., & Gay, F. (2021). Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3695-3703. https://doi.org/10.1158/1078-0432.CCR-21-0134
Zaccaria, Gian Maria, et al. "Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3695-3703. doi: https://doi.org/10.1158/1078-0432.CCR-21-0134
Zaccaria GM, Bertamini L, Petrucci MT, Offidani M, Corradini P, Capra A, Romano A, Liberati AM, Mannina D, de Fabritiis P, Cascavilla N, Ruggeri M, Mina R, Patriarca F, Benevolo G, Belotti A, Gaidano G, Nagler A, Hájek R, Spencer A, Sonneveld P, Musto P, Boccadoro M, Gay F. Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. Clin Cancer Res. 2021 Jul 01;27(13):3695-3703. doi: 10.1158/1078-0432.CCR-21-0134. Epub 2021 Apr 29. PMID: 33926915.
Copy Download .nbib Format: NLM
Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema.

Clinical ophthalmology (Auckland, N.Z.)

Bandello F, De Benedetto U, Knutsson KA, Parodi MB, Cascavilla ML, Iacono P.
PMID: 21966206
Clin Ophthalmol. 2011;5:1303-8. doi: 10.2147/OPTH.S17423. Epub 2011 Sep 14.

Diabetic macular edema is the major cause of visual acuity impairment in diabetic patients. The exact etiopathogenesis is unknown and, currently, grid/focal retinal laser photocoagulation represents the recommended treatment. It has been demonstrated that vascular endothelial growth factor (VEGF)...

Cite
Bandello F, De Benedetto U, Knutsson KA, et al. Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol. 2011;5:1303-8doi: 10.2147/OPTH.S17423.
Bandello, F., De Benedetto, U., Knutsson, K. A., Parodi, M. B., Cascavilla, M. L., & Iacono, P. (2011). Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clinical ophthalmology (Auckland, N.Z.), 51303-8. https://doi.org/10.2147/OPTH.S17423
Bandello, Francesco, et al. "Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema." Clinical ophthalmology (Auckland, N.Z.) vol. 5 (2011): 1303-8. doi: https://doi.org/10.2147/OPTH.S17423
Bandello F, De Benedetto U, Knutsson KA, Parodi MB, Cascavilla ML, Iacono P. Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol. 2011;5:1303-8. doi: 10.2147/OPTH.S17423. Epub 2011 Sep 14. PMID: 21966206; PMCID: PMC3180503.
Copy Download .nbib Format: NLM
Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients.

Frontiers in pediatrics

Frontino G, Raouf T, Canarutto D, Tirelli E, Di Tonno R, Rigamonti A, Cascavilla ML, Baldoli C, Scotti R, Leocani L, Huang SC, Meschi F, Barera G, Broccoli V, Rossi G, Torchio S, Chimienti R, Bonfanti R, Piemonti L.
PMID: 34970515
Front Pediatr. 2021 Dec 14;9:755365. doi: 10.3389/fped.2021.755365. eCollection 2021.

No abstract available.

Cite
Frontino G, Raouf T, Canarutto D, et al. Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients. Front Pediatr. 2021;9:755365doi: 10.3389/fped.2021.755365.
Frontino, G., Raouf, T., Canarutto, D., Tirelli, E., Di Tonno, R., Rigamonti, A., Cascavilla, M. L., Baldoli, C., Scotti, R., Leocani, L., Huang, S. C., Meschi, F., Barera, G., Broccoli, V., Rossi, G., Torchio, S., Chimienti, R., Bonfanti, R., & Piemonti, L. (2021). Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients. Frontiers in pediatrics, 9755365. https://doi.org/10.3389/fped.2021.755365
Frontino, Giulio, et al. "Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients." Frontiers in pediatrics vol. 9 (2021): 755365. doi: https://doi.org/10.3389/fped.2021.755365
Frontino G, Raouf T, Canarutto D, Tirelli E, Di Tonno R, Rigamonti A, Cascavilla ML, Baldoli C, Scotti R, Leocani L, Huang SC, Meschi F, Barera G, Broccoli V, Rossi G, Torchio S, Chimienti R, Bonfanti R, Piemonti L. Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients. Front Pediatr. 2021 Dec 14;9:755365. doi: 10.3389/fped.2021.755365. eCollection 2021. PMID: 34970515; PMCID: PMC8712700.
Copy Download .nbib Format: NLM
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score.

Blood cancer journal

D'Agostino M, Larocca A, Offidani M, Liberati AM, Gaidano G, Petrucci MT, Derudas D, Capra A, Zambello R, Cascavilla N, de Fabritiis P, Innao V, Bonello F, Patriarca F, Benevolo G, Giuliani N, Aitoro G, Guglielmelli T, Di Raimondo F, Corradini P, Musto P, Hájek R, Sonneveld P, Boccadoro M, Bringhen S.
PMID: 33846296
Blood Cancer J. 2021 Apr 12;11(4):73. doi: 10.1038/s41408-021-00464-w.

No abstract available.

Cite
D'Agostino M, Larocca A, Offidani M, et al. Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer J. 2021;11(4):73doi: 10.1038/s41408-021-00464-w.
D'Agostino, M., Larocca, A., Offidani, M., Liberati, A. M., Gaidano, G., Petrucci, M. T., Derudas, D., Capra, A., Zambello, R., Cascavilla, N., de Fabritiis, P., Innao, V., Bonello, F., Patriarca, F., Benevolo, G., Giuliani, N., Aitoro, G., Guglielmelli, T., Di Raimondo, F., Corradini, P., Musto, P., Hájek, R., Sonneveld, P., Boccadoro, M., & Bringhen, S. (2021). Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood cancer journal, 11(4), 73. https://doi.org/10.1038/s41408-021-00464-w
D'Agostino, Mattia, et al. "Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score." Blood cancer journal vol. 11,4 (2021): 73. doi: https://doi.org/10.1038/s41408-021-00464-w
D'Agostino M, Larocca A, Offidani M, Liberati AM, Gaidano G, Petrucci MT, Derudas D, Capra A, Zambello R, Cascavilla N, de Fabritiis P, Innao V, Bonello F, Patriarca F, Benevolo G, Giuliani N, Aitoro G, Guglielmelli T, Di Raimondo F, Corradini P, Musto P, Hájek R, Sonneveld P, Boccadoro M, Bringhen S. Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer J. 2021 Apr 12;11(4):73. doi: 10.1038/s41408-021-00464-w. PMID: 33846296; PMCID: PMC8041817.
Copy Download .nbib Format: NLM
Comparison of UW with other solutions for liver preservation in dogs.

Clinical transplantation

Todo S, Podesta L, Ueda Y, Imventarza O, Casavilla A, Oks A, Okuda K, Nalesnik M, Venkataramanan R, Starzl TE.
PMID: 21151798
Clin Transplant. 1989 Oct;3(5):253-259.

The efficacy of the University of Wisconsin (UW) solution was compared with conventional Euro-Collins solution, as well as with 3 variants of a silica gel solution developed at the University of Minnesota (UM). Protection of the liver grafts with...

Cite
Todo S, Podesta L, Ueda Y, et al. Comparison of UW with other solutions for liver preservation in dogs. Clin Transplant. 1989;3(5):253-259
Todo, S., Podesta, L., Ueda, Y., Imventarza, O., Casavilla, A., Oks, A., Okuda, K., Nalesnik, M., Venkataramanan, R., & Starzl, T. E. (1989). Comparison of UW with other solutions for liver preservation in dogs. Clinical transplantation, 3(5), 253-259.
Todo, S, et al. "Comparison of UW with other solutions for liver preservation in dogs." Clinical transplantation vol. 3,5 (1989): 253-259.
Todo S, Podesta L, Ueda Y, Imventarza O, Casavilla A, Oks A, Okuda K, Nalesnik M, Venkataramanan R, Starzl TE. Comparison of UW with other solutions for liver preservation in dogs. Clin Transplant. 1989 Oct;3(5):253-259. PMID: 21151798; PMCID: PMC3000168.
Copy Download .nbib Format: NLM
Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature.

Therapeutics and clinical risk management

Sgherza N, Abruzzese E, Perla G, Minervini MM, Chiello V, Sciannamè N, Cascavilla N.
PMID: 28721056
Ther Clin Risk Manag. 2017 Jun 27;13:751-755. doi: 10.2147/TCRM.S137103. eCollection 2017.

Approximately 10%-12% of patients in chronic-phase chronic myeloid leukemia (CP-CML) have additional chromosomal aberrations at diagnosis; moreover, CML occurs in up to 10% of pregnancy-associated leukemias, with an annual incidence of 1 per 100,000 pregnancies. In this report we...

Cite
Sgherza N, Abruzzese E, Perla G, et al. Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature. Ther Clin Risk Manag. 2017;13:751-755doi: 10.2147/TCRM.S137103.
Sgherza, N., Abruzzese, E., Perla, G., Minervini, M. M., Chiello, V., Sciannamè, N., & Cascavilla, N. (2017). Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature. Therapeutics and clinical risk management, 13751-755. https://doi.org/10.2147/TCRM.S137103
Sgherza, Nicola, et al. "Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature." Therapeutics and clinical risk management vol. 13 (2017): 751-755. doi: https://doi.org/10.2147/TCRM.S137103
Sgherza N, Abruzzese E, Perla G, Minervini MM, Chiello V, Sciannamè N, Cascavilla N. Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature. Ther Clin Risk Manag. 2017 Jun 27;13:751-755. doi: 10.2147/TCRM.S137103. eCollection 2017. PMID: 28721056; PMCID: PMC5499781.
Copy Download .nbib Format: NLM
Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study.

HIV medicine

Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A.
PMID: 29862615
HIV Med. 2018 Jun 04; doi: 10.1111/hiv.12624. Epub 2018 Jun 04.

OBJECTIVES: Lymphoproliferative disorders are often observed in HIV-positive patients. Combination antiretroviral treatment (cART) during antineoplastic chemotherapy is beneficial, but little is known about the clinical outcome according to different antiretroviral combinations. The aim of the study was to address...

Cite
Focà E, Cavaglià G, Rusconi S, et al. Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. HIV Med. 2018;doi: 10.1111/hiv.12624.
Focà, E., Cavaglià, G., Rusconi, S., Cascavilla, A., Cenderello, G., Re, A., Casari, S., van den Bogaart, L., Zinzani, P. L., Caracciolo, D., Di Perri, G., Bonito, A., Lucchini, A., Cassola, G., Viale, P., & Calcagno, A. (2018). Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. HIV medicine, . https://doi.org/10.1111/hiv.12624
Focà, E, et al. "Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study." HIV medicine vol. (2018). doi: https://doi.org/10.1111/hiv.12624
Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A. Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. HIV Med. 2018 Jun 04; doi: 10.1111/hiv.12624. Epub 2018 Jun 04. PMID: 29862615.
Copy Download .nbib Format: NLM
Combined Optic Atrophy and Rod-Cone Dystrophy Expands the RTN4IP1 (Optic Atrophy 10) Phenotype.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

Rajabian F, Manitto MP, Palombo F, Caporali L, Grazioli A, Starace V, Arrigo A, Cascavilla ML, La Morgia C, Barboni P, Bandello F, Carelli V, Battaglia Parodi M.
PMID: 33136666
J Neuroophthalmol. 2021 Sep 01;41(3):e290-e292. doi: 10.1097/WNO.0000000000001124.

No abstract available.

Cite
Rajabian F, Manitto MP, Palombo F, et al. Combined Optic Atrophy and Rod-Cone Dystrophy Expands the RTN4IP1 (Optic Atrophy 10) Phenotype. J Neuroophthalmol. 2021;41(3):e290-e292doi: 10.1097/WNO.0000000000001124.
Rajabian, F., Manitto, M. P., Palombo, F., Caporali, L., Grazioli, A., Starace, V., Arrigo, A., Cascavilla, M. L., La Morgia, C., Barboni, P., Bandello, F., Carelli, V., & Battaglia Parodi, M. (2021). Combined Optic Atrophy and Rod-Cone Dystrophy Expands the RTN4IP1 (Optic Atrophy 10) Phenotype. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 41(3), e290-e292. https://doi.org/10.1097/WNO.0000000000001124
Rajabian, Firuzeh, et al. "Combined Optic Atrophy and Rod-Cone Dystrophy Expands the RTN4IP1 (Optic Atrophy 10) Phenotype." Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society vol. 41,3 (2021): e290-e292. doi: https://doi.org/10.1097/WNO.0000000000001124
Rajabian F, Manitto MP, Palombo F, Caporali L, Grazioli A, Starace V, Arrigo A, Cascavilla ML, La Morgia C, Barboni P, Bandello F, Carelli V, Battaglia Parodi M. Combined Optic Atrophy and Rod-Cone Dystrophy Expands the RTN4IP1 (Optic Atrophy 10) Phenotype. J Neuroophthalmol. 2021 Sep 01;41(3):e290-e292. doi: 10.1097/WNO.0000000000001124. PMID: 33136666.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries